Jailendra Singh
Stock Analyst at Truist Securities
(0.93)
# 3,972
Out of 5,154 analysts
193
Total ratings
28.44%
Success rate
-25.83%
Average return
Main Sectors:
Stocks Rated by Jailendra Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems | Reiterates: Buy | $275 → $262 | $195.49 | +34.02% | 8 | Mar 5, 2026 | |
| PGNY Progyny | Maintains: Buy | $34 → $28 | $18.31 | +52.92% | 11 | Mar 2, 2026 | |
| PRVA Privia Health Group | Maintains: Buy | $31 → $33 | $23.27 | +41.81% | 9 | Mar 2, 2026 | |
| EVH Evolent Health | Maintains: Buy | $10 → $6 | $3.17 | +89.27% | 9 | Feb 26, 2026 | |
| HIMS Hims & Hers Health | Reiterates: Hold | $37 → $18 | $15.74 | +14.36% | 12 | Feb 24, 2026 | |
| IQV IQVIA Holdings | Maintains: Buy | $290 → $245 | $174.49 | +40.41% | 19 | Feb 19, 2026 | |
| WAY Waystar Holding | Maintains: Buy | $51 → $38 | $25.71 | +47.80% | 4 | Feb 18, 2026 | |
| MEDP Medpace Holdings | Maintains: Hold | $555 → $539 | $470.59 | +14.54% | 7 | Feb 11, 2026 | |
| DOCS Doximity | Maintains: Buy | $62 → $37 | $25.34 | +46.01% | 10 | Feb 6, 2026 | |
| MDLN Medline | Initiates: Buy | $52 | $43.83 | +18.64% | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $231 → $222 | $107.20 | +107.09% | 11 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $22 | $9.61 | +128.93% | 1 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $36 | $12.05 | +198.76% | 7 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $46.14 | +4.03% | 1 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $10 → $9 | $5.08 | +77.17% | 16 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6.5 → $5.5 | $2.28 | +141.23% | 12 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $12 → $7.5 | $5.46 | +37.36% | 7 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $46 | $24.91 | +84.66% | 5 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $14 | $11.15 | +25.56% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6.4 → $6.5 | $0.60 | +986.41% | 8 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $13 | $1.64 | +692.68% | 11 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $24 | $1.18 | +1,933.90% | 2 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $4 | $0.76 | +429.73% | 4 | Feb 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $58 | $217.78 | -73.37% | 2 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $90 → $45 | $1.72 | +2,516.28% | 7 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $230 → $333 | $919.26 | -63.78% | 6 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $9 | $2.00 | +350.00% | 2 | May 19, 2021 |
Veeva Systems
Mar 5, 2026
Reiterates: Buy
Price Target: $275 → $262
Current: $195.49
Upside: +34.02%
Progyny
Mar 2, 2026
Maintains: Buy
Price Target: $34 → $28
Current: $18.31
Upside: +52.92%
Privia Health Group
Mar 2, 2026
Maintains: Buy
Price Target: $31 → $33
Current: $23.27
Upside: +41.81%
Evolent Health
Feb 26, 2026
Maintains: Buy
Price Target: $10 → $6
Current: $3.17
Upside: +89.27%
Hims & Hers Health
Feb 24, 2026
Reiterates: Hold
Price Target: $37 → $18
Current: $15.74
Upside: +14.36%
IQVIA Holdings
Feb 19, 2026
Maintains: Buy
Price Target: $290 → $245
Current: $174.49
Upside: +40.41%
Waystar Holding
Feb 18, 2026
Maintains: Buy
Price Target: $51 → $38
Current: $25.71
Upside: +47.80%
Medpace Holdings
Feb 11, 2026
Maintains: Hold
Price Target: $555 → $539
Current: $470.59
Upside: +14.54%
Doximity
Feb 6, 2026
Maintains: Buy
Price Target: $62 → $37
Current: $25.34
Upside: +46.01%
Medline
Jan 12, 2026
Initiates: Buy
Price Target: $52
Current: $43.83
Upside: +18.64%
Jan 8, 2026
Downgrades: Hold
Price Target: $231 → $222
Current: $107.20
Upside: +107.09%
Jan 8, 2026
Upgrades: Buy
Price Target: $12 → $22
Current: $9.61
Upside: +128.93%
Sep 8, 2025
Maintains: Buy
Price Target: $35 → $36
Current: $12.05
Upside: +198.76%
Jun 16, 2025
Initiates: Buy
Price Target: $48
Current: $46.14
Upside: +4.03%
May 27, 2025
Maintains: Hold
Price Target: $10 → $9
Current: $5.08
Upside: +77.17%
Apr 10, 2025
Maintains: Hold
Price Target: $6.5 → $5.5
Current: $2.28
Upside: +141.23%
Apr 10, 2025
Maintains: Hold
Price Target: $12 → $7.5
Current: $5.46
Upside: +37.36%
Mar 18, 2025
Maintains: Buy
Price Target: $50 → $46
Current: $24.91
Upside: +84.66%
Jul 2, 2024
Maintains: Buy
Price Target: $17 → $14
Current: $11.15
Upside: +25.56%
May 24, 2024
Maintains: Hold
Price Target: $6.4 → $6.5
Current: $0.60
Upside: +986.41%
May 4, 2022
Maintains: Neutral
Price Target: $16 → $13
Current: $1.64
Upside: +692.68%
Feb 24, 2022
Maintains: Neutral
Price Target: $30 → $24
Current: $1.18
Upside: +1,933.90%
Feb 8, 2022
Downgrades: Neutral
Price Target: $14 → $4
Current: $0.76
Upside: +429.73%
Feb 4, 2022
Maintains: Neutral
Price Target: $60 → $58
Current: $217.78
Upside: -73.37%
Jan 7, 2022
Downgrades: Underperform
Price Target: $90 → $45
Current: $1.72
Upside: +2,516.28%
Jan 7, 2022
Upgrades: Outperform
Price Target: $230 → $333
Current: $919.26
Upside: -63.78%
May 19, 2021
Maintains: Neutral
Price Target: $10 → $9
Current: $2.00
Upside: +350.00%